GLP1R and Hypoglycemia: Pooled data from two studies including 1026 participants indicated lower occurrence of hypoglycaemia [RR= 0.32 (95% CI: 0.17-0.60); P< 0.01; I2 = 78%] as compared to insulin, GLP-1 RA; while in three studies with 393 participants, Tirzepatide showed higher incidence of hypoglycaemia [RR = 4.22 (95% CI: 1.26-14.15); P = 0.02; I2 = 0%] as compared to placebo [14].